Robert J. Rosenthal, Ph.D. Appointed to InVivo Therapeutics BOD

Northwell Health Ranked Nation’s Top Health System for Diversity

New York State’s largest health care provider and private employer made the list for the ninth straight year and remained in the top spot in the 2021 DiversityInc rankings for Hospitals and Health Systems.

ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

Kathy Sherwood Joins Pelvital USA, Inc. Board of Directors

Sherwood's experience, which includes a diverse group of medical product companies such as Boston Scientific, American Medical Systems, St. Jude Medical, Kinetic Concepts, Transoma Medical and Medtronic, gives her an understanding of the problems faced by both large and small companies.

Today InVivo Therapeutics Holdings Corp. announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent.

“Dr. Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations to strategic planning and capital market transactions, will be a highly valuable addition to our Board as we guide the Company forward toward its near- and long-term goals,” said Ann Merrifield, InVivo’s Chair of the Board of Directors.

Dr. Rosenthal currently serves as Chairman of the Board of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2018 he also served as Chief Executive Officer. Dr. Rosenthal also currently serves as a director of the Bruker Corporation, a publicly-traded manufacturer of analytic instruments, since 2015. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of its board of directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company, since 2013.

“I am excited to join the InVivo Board at this critical period in the company’s history, and I look forward to working together with the Board and the InVivo team as InVivo continues advancing down its clinical pathway to ultimately address an area of significant unmet need for spinal cord injury patients,” commented Dr. Rosenthal.

Dr. Rosenthal has more than 25 years of experience in a variety of senior management positions with companies involved in the development of therapeutics, medical devices, diagnostics and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc.

Dr. Rosenthal holds a Ph.D. from Emory University and a Master of Science degree from the State University of New York.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles